Linked Life Data

10741147

Source:http://linkedlifedata.com/resource/pubmed/id/10741147

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2000-6-20
pubmed:abstractText
New therapeutic strategies for indolent lymphomas are described. Relapsed or advanced staged follicular lymphoma is assumed to have an indolent course when compared with intermediate- and high-grade NHL. Although treatment of low-grade follicular lymphomas with standard chemotherapeutic regimens is characteristically associated with a high initial response rate, the clinical course consists of a pattern of repeated relapse. Subsequent remissions occur, but at a progressively lower rate and with a shorter duration. Patients eventually succumb to the disease or its complications with a median survival of approximately 6.2 years. For these reasons, novel therapeutic agents and strategies need to be evaluated in this group of patients. Recently, high-dose chemoradiotherapy with autologous hematopoietic stem cell transplantation with ex vivo purging method was reported to be very effective therapeutic strategy. Very promising reports of chimeric anti-CD20 monoclonal antibody(rituximab), radioimmunotherapy by radioisotope-conjugated monoclonal antibodies, interferon, and allogeneic mini-transplantation followed by non-myeloablative preconditioning regimens are reviewed. Recent therapeutic approaches for other subtypes of indolent lymphomas including MALT and mantle cell lymphoma are also reviewed.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0047-1852
pubmed:author
pubmed:issnType
Print
pubmed:volume
58
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
682-94
pubmed:dateRevised
2011-7-27
pubmed:meshHeading
pubmed-meshheading:10741147-Antibodies, Monoclonal, pubmed-meshheading:10741147-Antibodies, Monoclonal, Murine-Derived, pubmed-meshheading:10741147-Antineoplastic Agents, pubmed-meshheading:10741147-Bone Marrow Purging, pubmed-meshheading:10741147-Combined Modality Therapy, pubmed-meshheading:10741147-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:10741147-Humans, pubmed-meshheading:10741147-Interferon-alpha, pubmed-meshheading:10741147-Lymphoma, B-Cell, pubmed-meshheading:10741147-Lymphoma, B-Cell, Marginal Zone, pubmed-meshheading:10741147-Lymphoma, Follicular, pubmed-meshheading:10741147-Lymphoma, Mantle-Cell, pubmed-meshheading:10741147-Neoplasm Staging, pubmed-meshheading:10741147-Prognosis, pubmed-meshheading:10741147-Radioimmunotherapy, pubmed-meshheading:10741147-Transplantation, Autologous
pubmed:year
2000
pubmed:articleTitle
[Therapeutic advances for indolent lymphomas].
pubmed:publicationType
Journal Article, English Abstract, Review